Sp1178
HOW TO DELIVER AFFIRMING DIGESTIVE DISORDERS CARE FOR THE TRANSGENDER COMMUNITY
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
Presenter
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
TEMPORAL TRENDS AND RELATIVE RISKS OF INTESTINAL AND EXTRA-INTESTINAL CANCERS IN PERSONS WITH INFLAMMATORY BOWEL DISEASES: A POPULATION-BASED STUDY FROM A LARGE CANADIAN PROVINCE
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
